AbCellera Biologics Inc vs Best Buy Co Inc — how do they compare? AbCellera Biologics Inc trades at $9.16 (market cap $2.99B), while Best Buy Co Inc trades at $83.25 (market cap $17.55B). The key difference: Best Buy Co Inc is far larger — about 5.9× AbCellera Biologics Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BBY | |
|---|---|---|
Market Cap | $2.99B | $17.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $90.17 |
52-Week Low | $2.78 | $55.52 |
Enterprise Value | $2.58B | $19.93B |
Dividend Yield | — | 4.61% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.
Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →